Difference between revisions of "Interferon alfa-2a (Roferon-A)"
m |
m |
||
| Line 8: | Line 8: | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
*[[Basal cell and squamous cell skin cancer]] | *[[Basal cell and squamous cell skin cancer]] | ||
| + | *[[Chronic myelogenous leukemia]] | ||
*[[Follicular lymphoma]] | *[[Follicular lymphoma]] | ||
*[[Melanoma]] | *[[Melanoma]] | ||
| Line 16: | Line 17: | ||
==Patient drug information== | ==Patient drug information== | ||
*[http://chemocare.com/BIO/interferon_alfa.asp Interferon alfa-2a (Roferon-A) patient drug information (Chemocare)]<ref>[http://chemocare.com/BIO/interferon_alfa.asp Interferon alfa-2a (Roferon-A) patient drug information (Chemocare)]</ref> | *[http://chemocare.com/BIO/interferon_alfa.asp Interferon alfa-2a (Roferon-A) patient drug information (Chemocare)]<ref>[http://chemocare.com/BIO/interferon_alfa.asp Interferon alfa-2a (Roferon-A) patient drug information (Chemocare)]</ref> | ||
| + | |||
| + | ==History of changes in FDA indication== | ||
| + | *6/4/1986: Initial FDA approval | ||
==References== | ==References== | ||
<references/> | <references/> | ||
| + | [[Category:Drug index]] | ||
[[Category:Immunotherapy]] | [[Category:Immunotherapy]] | ||
| Line 29: | Line 34: | ||
[[Category:Renal cancer medications]] | [[Category:Renal cancer medications]] | ||
[[Category:Transplant medications]] | [[Category:Transplant medications]] | ||
| + | |||
| + | [[Category:Drugs FDA approved in 1986]] | ||
Revision as of 15:36, 8 November 2014
General information
Class/mechanism: Immune system activator; binds to human type 1 interferon, activating downstream intracellular signal transduction pathways initially mediated by the JAK/STAT pathway. Interferon α-2a activates multiple biologic effects which are not fully understood.[1][2]
Route: SC
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- Basal cell and squamous cell skin cancer
- Chronic myelogenous leukemia
- Follicular lymphoma
- Melanoma
- Neuroendocrine tumors
- Renal cancer
- Transplant conditioning regimens
Patient drug information
History of changes in FDA indication
- 6/4/1986: Initial FDA approval